Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Insights into Europe’s covid-19 testing and technology use 2021-2022: PCR v serology v antigen Europe is shifting its covid-19-approach from pandemic to… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Europe | IVD Gateway | Molecular Diagnostics (MDx)
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT) | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
2022 healthcare megatrends shaping the surgical-device sector This infographic looks at three trends in healthcare that… General surgery | Minimally invasive surgery | Orthopaedic & Spine Surgery | Surgical device and IVD | Asia | Europe | Middle East & Africa | Cardiovascular Surgery | Minimally invasive surgery | Orthopaedic & Spine Surgery | Robotic surgery | Surgical Gateway | Urology
Cancer and tissue diagnostics market outlook Tissue diagnostics (TDx) play an important role in improving… Cancer diagnostics | In-vitro diagnostics | Tissue Diagnostics (TDx) | Americas | Asia | Europe | IVD Gateway | Tissue Diagnostics (TDx)
[On-demand Webinar] Covid-19 Impact: Molecular Diagnostic (MDx) Market EIU Healthcare zooms in on two of the fastest-growing… Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Asia | Europe | Global | IVD Gateway | Molecular Diagnostics (MDx)
Covid-19 Testing Monitor: More than Seven-fold Increase in Diagnostic Testing Volume in the US, Brazil and India EIU Healthcare has launched the Covid-19 Testing Monitor –… Covid-19 testing | In-vitro diagnostics | Americas | Asia | Europe | Global | IVD Gateway
European IVD Market: Pre- and Post-Covid-19 In our white paper “The European IVD Market Landscape… Covid-19 testing | In-vitro diagnostics | Europe | IVD Gateway
Robotic Surgery: Trends in Urology In this infographic, we look at urological surgery trends, a… Robotic surgery | Surgical device and IVD | Asia | Europe | Surgical Gateway